Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy.

Kuksa, L; Andrejak, C; Haecker, B; Bothamley, G; Calcagno, A; M Cirillo, D; Duarte, R; Fatima, R; Ferlazzo, G; Guglielmetti, L; Günther, G; Hewison, C; R Horsburgh, C; Jäger, T; Kalancha, Y; Otto-Knapp, R; Kranzer, K; Lillebaek, T; Marks, G; Middelkoop, K; Motta, I; Rabinova, V; Sommerfeld, P; Tattevin, P; Lange, C

doi:10.5588/ijtldopen.25.0152

Public

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy.

Shared by NobleBlocks on Mar 1, 2025 • 12:00 AM UTC

Authors:

L Kuksa

C Andrejak

B Haecker

Abstract

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, "when antib...

Subject

European Medicines Agency

MDR-TB

RR-TB

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!